Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 185, Issue 4, Pages 656-669Publisher
WILEY
DOI: 10.1111/bjh.15802
Keywords
chronic lymphocytic leukaemia; B cell receptor inhibitor; ibrutinib; idelalisib; p53 venetoclax; BCL2
Categories
Funding
- Oxford NIHR Biomedical Research Centre
Ask authors/readers for more resources
Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi-centre retrospective analysis of 105 R/R CLL patients who received venetoclax pre-National Health Service commissioning. The median age was 67 years and median prior lines was 3 (range: 1-15). 48% had TP53 disruption. At >= 2 lines, 60% received a Bruton Tyrosine Kinase inhibitor (BTKi) and no prior phosphoinositide 3-kinase inhibitor (Pi3Ki), 25% received a Pi3Ki and no prior BTKi, and 10% received both. Patients discontinued B cell receptor inhibitor (BCRi) because of toxicity in 44% and progression in 54%. Tumour lysis syndrome risk was low, intermediate or high in 27%, 25%, and 48% respectively. Overall response was 88% (30% complete response [CR]). The overall response rate was 85% (CR 23%) in BTKi-exposed patients, 92% (CR 38%) in Pi3Ki-exposed patients and 80% (CR 20%) in both (P = 0 center dot 59). With a median follow-up of 15 center dot 6 months, 1-year progression-free survival was 65 center dot 0% and 1-year overall survival was 75 center dot 1%. Dose reduction or temporary interruption did not result in an inferior progression-free or discontinuation-free survival. Risk of progression or death after stopping a prior BCRi for progression was double compared to those stopping for other reasons (predominantly toxicity) (Hazard Ratio 2 center dot 01 P = 0 center dot 05). Venetoclax is active and well tolerated in R/R CLL post >= 1 BCRi. Reason(s) for stopping BCRi influences venetoclax outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available